➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Colorcon
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CEDAZURIDINE; DECITABINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Cedazuridine; Decitabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03306264 Phase 3 Study of ASTX727 vs IV Decitabine in MDS and CMML Not yet recruiting Astex Pharmaceuticals Phase 3 2017-12-01 Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily×5 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, subjects will continue to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the subject discontinues treatment or withdraws from the study.
NCT03502668 Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS Recruiting Chiltern International Inc. Phase 1/Phase 2 2018-07-27 Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with IPSS risk category of low-risk or Intermediate-1 MDS. In Phase 1 Stage A, subjects will be randomized in a 1:1:1 ratio into 3 cohorts of 6 subjects each in a 10-day schedule in 28-day cycles; when safety is established in Stage A, 24 evaluable subjects will be randomized in a 1:1:1:1 ratio in Phase 1 Stage B into 4 cohorts of 6 subjects each in a 14-day schedule in 28-day cycles. In Phase 2, 40 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules selected from Phase 1.
NCT03502668 Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS Recruiting Astex Pharmaceuticals Phase 1/Phase 2 2018-07-27 Multicenter, open-label study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with IPSS risk category of low-risk or Intermediate-1 MDS. In Phase 1 Stage A, subjects will be randomized in a 1:1:1 ratio into 3 cohorts of 6 subjects each in a 10-day schedule in 28-day cycles; when safety is established in Stage A, 24 evaluable subjects will be randomized in a 1:1:1:1 ratio in Phase 1 Stage B into 4 cohorts of 6 subjects each in a 14-day schedule in 28-day cycles. In Phase 2, 40 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules selected from Phase 1.
NCT03813186 Effect of Food on Blood Levels of ASTX727 Recruiting Astex Pharmaceuticals Phase 1 2018-11-08 This study is designed to examine blood levels of ASTX727, a fixed-dose combination tablet containing the combination of cedazuridine (100 mg) and decitabine (35 mg), when given under fed versus fasted conditions to participants with myelodysplastic syndromes (MDS), including refractory anemia with excess blasts in transformation or chronic myelomonocytic leukemia (CMML). This study will also assess the safety of ASTX727.
NCT03875287 Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors Not yet recruiting Astex Pharmaceuticals Phase 1 2019-03-01 This is a phase 1 study of the combination of cedazuridine with decitabine in patients with solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal hypomethylation and toxicity (up to 30 patients total).
NCT03875287 Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors Not yet recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 2019-03-01 This is a phase 1 study of the combination of cedazuridine with decitabine in patients with solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal hypomethylation and toxicity (up to 30 patients total).
NCT03922555 ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas Not yet recruiting Astex Pharmaceuticals Phase 1 2019-05-31 this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cedazuridine; Decitabine

Condition Name

Condition Name for Cedazuridine; Decitabine
Intervention Trials
Myelodysplastic Syndromes 3
Chronic Myelomonocytic Leukemia 2
Solid Tumor 1
Neurological Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cedazuridine; Decitabine
Intervention Trials
Syndrome 3
Preleukemia 3
Myelodysplastic Syndromes 3
Leukemia, Myelomonocytic, Chronic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cedazuridine; Decitabine

Trials by Country

Trials by Country for Cedazuridine; Decitabine
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cedazuridine; Decitabine
Location Trials
Massachusetts 1
Maryland 1
Ohio 1
Michigan 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cedazuridine; Decitabine

Clinical Trial Phase

Clinical Trial Phase for Cedazuridine; Decitabine
Clinical Trial Phase Trials
Phase 3 1
Phase 1/Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cedazuridine; Decitabine
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cedazuridine; Decitabine

Sponsor Name

Sponsor Name for Cedazuridine; Decitabine
Sponsor Trials
Astex Pharmaceuticals 6
Michael Savona 1
Theradex 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cedazuridine; Decitabine
Sponsor Trials
Industry 9
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Johnson and Johnson
McKesson
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.